Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?

  • 2021-02-18
  • Admin System

 

Editorial: incorporating liver stiffness to risk scores for HCC in patients with chronic hepatitis B treated with oral antivirals: ready to use or not?

Hwai-I Yang
Aliment Pharmacol Ther
February 18, 2021

Risk prediction models (scores) for hepatocellular carcinoma (HCC) contribute to risk stratification, management and HCC surveillance for patients with chronic hepatitis B (CHB). In this editorial, we commented on a study which investigated whether the addition of LS values could enhance the predictive accuracies of the PAGE-B related scores using Korean CHB patients who initiated treatment with entecavir or tenofovir between 2007 and 2017. We pointed out some methodologic issues to be clarified before concluding the superiority of the newly-developed score over the original PAGE-B related scores. We also suggested further validation studies to judge whether the addition of LS values enhances the predictive accuracy of the PAGE-B related models or those based on the diagnosis of cirrhosis.

Full content